Dysplastic nevus: almost 40 years later


如何引用文章

全文:

详细

The biological significance of dysplastic nevuses remains an object of discussion up to the present time, despite the fact that a dysplastic nevus is a high risk marker of malignant cutaneous melanoma. The role of these nevuses as direct precursors of melanoma is less certain. The authors present the results of research in this sphere, carried out over the recent decades since the fist description of dysplastic nevuses in 1978.

作者简介

I. Salamova

Health Center No. 3, Administration of the President of the Russian Federation

кандидат мед. наук. 129090, Moscow, Russia

Veronica Mordovtseva

Moscow State University of Foodstuff Production

Email: gveesha@mail.ru
MD, PhD, DSc, prof. 125080, Moscow, Russia

参考

  1. Clark W.H. Jr., Reimer R.R., Greene M., Ainsworth A.M., Mastrangelo M.J. Origin of familial malignant melanomas from heritable melanocytic lesions. «The B-K mole syndrome». Arch. Dermatol. 1978; 114(5): 732-8.
  2. Ackerman A.B., Magana-Garcia M. Naming acquired melanocytic nevi: Unna’s, Miescher’s, Spitz’s Clark’s. Am. J. Dermatopathol. 1990; 12(2): 193-209.
  3. Barnhill R.L., Cerroni L., Cook M., Elder D.E., Kerl H., LeBoit P.E., et al. State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv. Anat. Pathol. 2010; 17(2): 73-90.
  4. Clarke L.E. Dysplastic nevi. Clin. Lab. Med. 2011; 31(2): 255-65.
  5. Chen S. The dysplastic nevus controversy: It is not about the nevus per se but one’s belief in the multistep tumorigenesis theory. Am. J. Dermatopathol. 2010; 32(8): 858. doi: 10.1097/DAD.0b013e3181dc0fda.
  6. Gao L., van den Hurk K., Moerkerk P.T., Goeman J.J., Beck S., Gruis N.A., et al. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy. J. Invest. Dermatol. 2014; 134(12): 2957-66. doi: 10.1038/jid.2014.270.
  7. Clark W.H.Jr., Ackerman A.B. An exchange of views regarding the dysplastic nevus controversy. Semin. Dermatol. 1989; 8(4): 229-50.
  8. Cesinaro A.M. Clinico-pathological impact of fibroplasia in melanocytic nevi: a critical revision of 209 cases. APMIS. 2012; 120(8): 658-65.
  9. Elder D.E. Dysplastic naevi: An update. Histopathology. 2010; 56(1): 112-20. doi: 10.1111/j.1365-2559.2009.03450
  10. Madan R., Chen S. The so-called dysplastic nevus is not dysplastic at all. Dermatol. Pract. Concept. 2013; 3(1): 1-2. doi: 10.5826/dpc.0301a01.
  11. Ackerman A.B. Critique of definitions about melanocytic proliferations formulated by an N.I.H. panel. Am. J. Dermatopathol. 1992; 14(3): 238-44.
  12. Shapiro M., Chren M.M., Levy R.M., Elder D.E., LeBoit P.E., Mihm M.C.Jr., et al. Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J. Cutan. Pathol. 2004; 31(8): 523-30.
  13. Rudolph P. The dysplastic nevus. An Ariadne’s thread through a conceptual labyrinth . Pathologe. 2002; 23(2): 128-34.
  14. Falchi M., Bataille V., Hayward N.K., Duffy D.L., Bishop J.A., Pastinen T., et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat. Genet. 2009; 41(8): 915-9. doi: 10.1038/ng.410.
  15. Nielsen K., Harbst K., Måsbäck A., Jönsson G., Borg A., Olsson H., et al. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype. Melanoma Res. 2010; 20(4): 266-72.
  16. Liang X., Pfeiffer R.M., Li W.Q., Brossard M., Burke L.S., Wheeler W., et al. Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families. J. Invest. Dermatol. 2014; 134(2): 481-7.
  17. Bishop D.T., Demenais F., Iles M.M. Genome wide association study identifies three loci associated with melanoma risk. Nat. Genet. 2009; 41(8): 920-5.
  18. Celebi J.T., Ward K.M., Wanner M., Polsky D., Kopf A.W. Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Clin. Exp. Dermatol. 2005; 30(1): 68-70.
  19. Decarlo K., Yang S., Emley A., Wajapeyee N., Green M., Mahalingam M. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7-challenging the concept of dysplastic nevi as precursor lesions? Hum. Pathol. 2010; 41(6): 886-94. doi: 10.1016/j.humpath.2009.12.002.
  20. McMeniman E., De’Ambrosis K., De’Ambrosis B. Risk factors in a cohort of patients with multiple primary melanoma. Australas J. Dermatol. 2010; 51(4): 254-7.
  21. Lee T.K., Rivers J.K., Gallagher R.P. Site-specific protective effect of broad-spectrum sunscreen on nevus development among white schoolchildren in a randomized trial. J. Am. Acad. Dermatol. 2005; 52(5): 786-92.
  22. Bataille V. Melanoma. Shall we move away from the sun and focus more on embryogenesis, body weight and longevity? Med. Hypotheses. 2013; 81(5): 846-50. doi: 10.1016/j.mehy.2013.05.031.
  23. Larue L., de Vuyst F., Delmas V. Modeling melanoblast development. Cell Mol. Life Sci. 2013; 70(6): 1067-79. doi: 10.1007/s00018-012-1112-4.
  24. Саламова И.В., Мордовцева В.В., Ламоткин И.А., Гладько В.В. Редкие случаи дисплазии в невусах головы и шеи. Экспериментальная и клиническая дерматокосметология. 2013; 4: 53-6.
  25. Bodelon C., Pfeiffer R.M., Bollati V., Debbache J., Calista D., Ghiorzo P., et al. On the interplay of telomeres, nevi and the risk of melanoma. PLoS One. 2012; 7(12): e52466. doi: 10.1371/journal.pone.0052466.

版权所有 © Eco-Vector, 2015


 


##common.cookie##